Rocío Marisol Espinoza-Chávez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rocío Marisol Espinoza-Chávez has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Adriano Defini Andricopulo
Laboratory of Medicinal and Computational Chemistry (LQMC), Centre for Research and Innovation in Biodiversity and Drug Discovery (CIBFar), São Carlos Institute of Physics (IFSC), University of São Paulo (USP), Av. João Dagnone, 1100, São Carlos 13563-120, SP, Brazil
4 shared publications - Celso de Oliveira Rezende Júnior
Laboratório de Síntese de Candidatos a Fármacos Instituto de Química Universidade Federal de Uberlândia (UFU) Uberlândia Minas Gerais Brazil
4 shared publications - Leonardo Luiz Gomes Ferreira
Laboratório de Química Medicinal e Computacional (LQMC) Instituto de Física de São Carlos (IFSC) Universidade de São Paulo (USP) São Carlos São Paulo Brazil
3 shared publications - Luiz Carlos Dias
Institute of Chemistry, University of Campinas, Barão Geraldo, PO Box 6154, Campinas, SP 13083-970, Brazil
3 shared publications - Mariana Laureano de Souza
University of California San Diego
2 shared publications Renata Krogh
Laboratory of Medicinal & Computational Chemistry, São Carlos Institute of Physics, University of São Paulo, São Carlos-SP, 13563-120, Brazil
2 shared publications
Latest Publications
- 17 February 2026
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 36 (1)
In Silico Analysis of Active Compounds of Peruvian Medicinal Plants with Antifungal Activity
- 17 February 2026
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 36 (1)
In Silico Analysis of Active Compounds of Peruvian Medicinal Plants with Antifungal Activity
- 27 August 2024
- Published by Wiley in ChemMedChem
- Vol. 19 (20) , e202400293
Structure‐Metabolism Relationships of Benzimidazole Derivatives with anti‐Trypanosoma cruzi Activity for Chagas Disease
This study introduces further insights from the hit‐to‐lead optimization process involving a series of benzimidazole derivatives acting as inhibitors of the cruzain enzyme, which targets Trypanosoma cruzi, the causative parasite of Chagas disease. Here, we present the design, synthesis and biological evaluation of 30 new compounds as a third generation of benzimidazole analogues with trypanocidal activity, aiming to enhance our understanding of their pharmacokinetic profiles and establish a structure‐metabolism relationships within the series. The design of these new analogues was guided by the analysis of previous pharmacokinetic results, considering identified metabolic sites and biotransformation studies. This optimization resulted in the discovery of two compounds (42 e and 49 b) exhibiting enhanced metabolic stability, anti‐Trypanosoma cruzi activity compared to benznidazole (the reference drug for Chagas disease), as well as being non‐cruzain inhibitors, and demonstrating a satisfactory in vitro pharmacokinetic profile. These findings unveil a new subclass of aminobenzimidazole and rigid compounds, which offer potential for further exploration in the quest for discovering novel classes of antichagasic compounds.
- 27 August 2024
- Published by Wiley in ChemMedChem
- Vol. 19 (20) , e202400293
Structure‐Metabolism Relationships of Benzimidazole Derivatives with anti‐Trypanosoma cruzi Activity for Chagas Disease
This study introduces further insights from the hit‐to‐lead optimization process involving a series of benzimidazole derivatives acting as inhibitors of the cruzain enzyme, which targets Trypanosoma cruzi, the causative parasite of Chagas disease. Here, we present the design, synthesis and biological evaluation of 30 new compounds as a third generation of benzimidazole analogues with trypanocidal activity, aiming to enhance our understanding of their pharmacokinetic profiles and establish a structure‐metabolism relationships within the series. The design of these new analogues was guided by the analysis of previous pharmacokinetic results, considering identified metabolic sites and biotransformation studies. This optimization resulted in the discovery of two compounds (42 e and 49 b) exhibiting enhanced metabolic stability, anti‐Trypanosoma cruzi activity compared to benznidazole (the reference drug for Chagas disease), as well as being non‐cruzain inhibitors, and demonstrating a satisfactory in vitro pharmacokinetic profile. These findings unveil a new subclass of aminobenzimidazole and rigid compounds, which offer potential for further exploration in the quest for discovering novel classes of antichagasic compounds.
- 9 January 2024
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 16 (3) , 253-269
Structure–Activity Relationships of Novel N -Imidazoylpiperazines with Potent Anti- Trypanosoma Cruzi Activity
Background: Chagas disease is caused by the parasite Trypanosoma cruzi, and the lack of effective and safe treatments makes identifying new classes of compounds with anti-T. cruzi activity of param... Graphical abstract
- 9 January 2024
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 16 (3) , 253-269
Structure–Activity Relationships of Novel N -Imidazoylpiperazines with Potent Anti- Trypanosoma Cruzi Activity
Background: Chagas disease is caused by the parasite Trypanosoma cruzi, and the lack of effective and safe treatments makes identifying new classes of compounds with anti-T. cruzi activity of param... Graphical abstract
- Open Access
- 15 December 2022
- Published by American Chemical Society (ACS) in ACS Bio & Med Chem Au
- Vol. 3 (1) , 32-45
Targeted Protein Degradation for Infectious Diseases: from Basic Biology to Drug Discovery
- 15 December 2022
- Published by American Chemical Society (ACS) in ACS Bio & Med Chem Au
- Vol. 3 (1) , 32-45
Open AccessTargeted Protein Degradation for Infectious Diseases: from Basic Biology to Drug Discovery
- Open Access
- 15 April 2021
- Published by MDPI AG in Biomolecules
- Vol. 11 (4) , 579
Chemoinformatics Studies on a Series of Imidazoles as Cruzain Inhibitors
Natural products based on imidazole scaffolds have inspired the discovery of a wide variety of bioactive compounds. Herein, a series of imidazoles that act as competitive and potent cruzain inhibitors was investigated using a combination of ligand- and structure-based drug design strategies. Quantitative structure–activity relationships (QSARs) were generated along with the investigation of enzyme–inhibitor molecular interactions. Predictive hologram QSAR (HQSAR, r2pred = 0.80) and AutoQSAR (q2 = 0.90) models were built, and key structural properties that underpin cruzain inhibition were identified. Moreover, comparative molecular field analysis (CoMFA, r2pred = 0.81) and comparative molecular similarity indices analysis (CoMSIA, r2pred = 0.73) revealed 3D molecular features that strongly affect the activity of the inhibitors. These findings were examined along with molecular docking studies and were highly compatible with the intermolecular contacts that take place between cruzain and the inhibitors. The results gathered herein revealed the main factors that determine the activity of the imidazoles studied and provide novel knowledge for the design of improved cruzain inhibitors.
- 15 April 2021
- Published by MDPI AG in Biomolecules
- Vol. 11 (4) , 579
Open AccessChemoinformatics Studies on a Series of Imidazoles as Cruzain Inhibitors
Natural products based on imidazole scaffolds have inspired the discovery of a wide variety of bioactive compounds. Herein, a series of imidazoles that act as competitive and potent cruzain inhibitors was investigated using a combination of ligand- and structure-based drug design strategies. Quantitative structure–activity relationships (QSARs) were generated along with the investigation of enzyme–inhibitor molecular interactions. Predictive hologram QSAR (HQSAR, r2pred = 0.80) and AutoQSAR (q2 = 0.90) models were built, and key structural properties that underpin cruzain inhibition were identified. Moreover, comparative molecular field analysis (CoMFA, r2pred = 0.81) and comparative molecular similarity indices analysis (CoMSIA, r2pred = 0.73) revealed 3D molecular features that strongly affect the activity of the inhibitors. These findings were examined along with molecular docking studies and were highly compatible with the intermolecular contacts that take place between cruzain and the inhibitors. The results gathered herein revealed the main factors that determine the activity of the imidazoles studied and provide novel knowledge for the design of improved cruzain inhibitors.
- 25 November 2019
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 60 (2) , 1028-1041
Discovery of Potent, Reversible, and Competitive Cruzain Inhibitors with Trypanocidal Activity: A Structure-Based Drug Design Approach
A virtual screening conducted with nearly 4,000,000 compounds from lead-like and fragment-like subsets enabled the identification of a small-molecule inhibitor (1) of the Trypanosoma cruzi cruzain enzyme, a validated drug target for Chagas disease. Subsequent comprehensive structure-based drug design and structure-activity relationship studies led to the discovery of carbamoyl imidazoles as potent, reversible and competitive cruzain inhibitors. The most potent carbamoyl imidazole inhibitor (45) exhibited high affinity with a Ki value of 20 nM, presenting both in vitro and in vivo activity against T. cruzi. Furthermore, the most promising compounds reduced parasite burden in vivo and showed no toxicity at a dose of 100 mg/kg. These carbamoyl imidazoles are structurally attractive, nonpeptidic, and easy to prepare and synthetically modify. Finally, these results further advance our understanding of the noncovalent mode of inhibition of this pharmaceutically relevant enzyme, building strong foundations for drug discovery efforts.
- 25 November 2019
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 60 (2) , 1028-1041
Discovery of Potent, Reversible, and Competitive Cruzain Inhibitors with Trypanocidal Activity: A Structure-Based Drug Design Approach
A virtual screening conducted with nearly 4,000,000 compounds from lead-like and fragment-like subsets enabled the identification of a small-molecule inhibitor (1) of the Trypanosoma cruzi cruzain enzyme, a validated drug target for Chagas disease. Subsequent comprehensive structure-based drug design and structure-activity relationship studies led to the discovery of carbamoyl imidazoles as potent, reversible and competitive cruzain inhibitors. The most potent carbamoyl imidazole inhibitor (45) exhibited high affinity with a Ki value of 20 nM, presenting both in vitro and in vivo activity against T. cruzi. Furthermore, the most promising compounds reduced parasite burden in vivo and showed no toxicity at a dose of 100 mg/kg. These carbamoyl imidazoles are structurally attractive, nonpeptidic, and easy to prepare and synthetically modify. Finally, these results further advance our understanding of the noncovalent mode of inhibition of this pharmaceutically relevant enzyme, building strong foundations for drug discovery efforts.